(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
02 September 2021 (02.09.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/173936 A1

(51) International Patent Classification:
A61K 31/4709 (2006.01) *A61K 9/20* (2006.01)

(21) International Application Number:
PCT/US2021/019825

(22) International Filing Date:
26 February 2021 (26.02.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/982,456 27 February 2020 (27.02.2020) US

(71) Applicant: **BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.** [US/US]; 215 Church Street, New Haven, Connecticut 06510 (US).

(72) Inventors: **CORIC, Vladimir**; 215 Church Street, New Haven, Connecticut 06510 (US). **CONWAY, Charles M.**; 215 Church Street, New Haven, Connecticut 06510 (US). **CROOP, Robert**; 215 Church Street, New Haven, Connecticut 06510 (US). **FROST, Marianne**; 215 Church Street, New Haven, Connecticut 06510 (US).


(74) Agent: **ZUEV, Dmitry**; 215 Church Street, New Haven, Connecticut 06510 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: ORAL FAST-DISPERSING DOSAGE FORM OF RIMEGEPANT

FIG. 1



(57) Abstract: Provided is a fast-dispersing dosage form for oral delivery, wherein the fast-dispersing dosage form includes a rimegepant. Also provided is a method for delivering rimegepant to a subject, wherein the method includes orally administering to the subject a fast-dispersing dosage form including rimegepant.

[Continued on next page]

WO 2021/173936 A1

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*
— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*